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Abstract
The outcomes of children with congenital hemolytic anemia (CHA) undergoing total splenectomy
(TS) or partial splenectomy (PS) remain unclear. In this study, we collected data from 100
children with CHA who underwent TS or PS from 2005–2013 at 16 sites in the Splenectomy in
Congenital Hemolytic Anemia (SICHA) consortium using a patient registry. We analyzed
demographics and baseline clinical status, operative details, and outcomes at 4, 24, and 52 weeks
after surgery. Results were summarized as hematologic outcomes, short-term adverse events
(AEs) (≤ 30 days after surgery), and long-term AEs (31–365 days after surgery). For children with
hereditary spherocytosis, after surgery there was an increase in hemoglobin (baseline 10.1 ± 1.8
gm/dl, 52 week 12.8 ± 1.6 gm/dl; mean ± SD), decrease in reticulocyte and bilirubin as well as
control of symptoms. Children with sickle cell disease had control of clinical symptoms after
surgery, but had no change in hematologic parameters. There was an 11% rate of short-term AEs
and 11% rate of long-term AEs. As we accumulate more subjects and longer follow-up, use of a
patient registry should enhance our capacity for clinical trials and engage all stakeholders in the
decision-making process.
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Introduction
For severely affected children with congenital hemolytic anemia (CHA), a splenectomy can
control hemolysis and limit sequestration crises [1]. However, the risks associated with total
splenectomy (TS) such as sepsis, thrombosis, or pulmonary hypertension have led to
increasing interest in partial splenectomy (PS). A PS is designed to remove enough spleen to
gain the desired hematological outcome while preserving splenic function [1–4]. Although
PS has been increasingly used for children with CHA, a prospective clinical trial comparing
surgical therapies or surgical versus medical therapies has not been done [3].
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Recent health care initiatives have demonstrated the value of evidence-based practices based
on large clinical datasets [5, 6]. However, the use of standard datasets for the study of
surgical procedures and less common conditions is difficult, as these sets often do not record
outcomes considered most important by clinicians and families [3, 7, 8]. In addition,
research on spleen surgery in CHA is challenged by the heterogeneity of diseases, small
number of subjects, variations in technique, and inconsistent use of standardized data [3]. In
these settings, a patient registry is a powerful tool to collect data to guide clinical therapies.
To improve the care of children with CHA, we formed SICHA (Splenectomy in Congenital
Hemolytic Anemia), a research consortium of pediatric surgeons and hematologists at 16
sites across North America. To help families and clinicians understand the outcomes of
spleen surgery for CHA and to support the development of clinical trials, our consortium
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developed a web-based patient registry to collect standardized data for children with CHA
undergoing TS or PS. The goal of this report is to describe the outcomes for first 100
children in this registry over one year of follow-up. The secondary goal of this report is to
assess data quality in this registry.

Methods
Registry design
To collect outcomes of children undergoing PS or TS, we created a web-based registry using
the Research Electronic Data Capture (REDCap) platform, which is an open-source
application for clinical research used by over 1000 partners in the National Institutes of
Health Clinical and Translational Science Awards consortium [9]. For registry design, all
site investigators first identified important issues for a family and clinician considering
spleen surgery, based on our consortium’s previous comparative effectiveness review.[3]
These concerns include the need use of standardized data and definitions of all outcomes,
analyses of disease type, and need for multicenter study.

NIH-PA Author Manuscript

Given these goals, we constructed a data dictionary to record important variables, which
were agreed upon by all site investigators. Our registry incorporated principles as described
by the Agency for Health Care Research and Quality, including the a priori identification of
clinical questions, a web-based interface for data entry, and use of established data
standards.[10] All site research staff underwent training via a webinar, and we developed a
Manual of Procedures (MOP) to ensure consistent practices across sites.
Subject enrollment
Children 2–17 years of age were eligible if they had a diagnosis of a CHA and underwent
TS or PS at a SICHA site between 2005 and 2013 (See Appendix for site roster). Diagnoses
included hereditary spherocytosis (HS), sickle cell disease (SCD, including hemoglobin SS,
SC, S-beta thalassemia), or other type of CHA. All diseases were defined using standard
clinical criteria, including family history, laboratory analysis, or genetic analysis as
appropriate [3]. Other indications for splenectomy, such as trauma or idiopathic
thrombocytopenia purpura were excluded.
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Each site’s institutional Review Board (IRB) approved this study, and each site retained all
identifying information. If a family chose to participate, staff obtained written informed
consent from the parents or guardians. As only de-identified data were collected centrally
into the registry, the registry was designated as exempt from IRB review. A Data Use
Agreement was executed between each site and the central coordinating center to enhance
data exchange.
Data were collected prospectively from 76 children from 2008–2014 and retrospectively
from 24 children from 2005–2008. There were 8 eligible children reported to the central
coordinating center whose parents declined enrollment, although the total number of eligible
children who were not enrolled was not collected. To test feasibility of this registry, we pilot
tested it at a single site and previously reported these findings in 24 children with SCD [11].
Based on this pilot experience, we eliminated extraneous variables, refined technical aspects
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of the data entry, and expanded inclusion to multiple types of CHA prior to rollout as a
multicenter registry.
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As an observational registry, this study did not dictate any clinical care, including the choice
between TS and PS, use of laparoscopy or laparotomy, specific laboratory testing, or use of
concurrent surgical procedures, although all of these outcomes were collected. For children
undergoing partial splenectomy, we encouraged maintenance of 10%–20% of normal
splenic volume, based on previous clinical and laboratory studies [3, 12–14].
Data abstraction
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We collected demographics and clinical status at baseline, operative data, and outcomes at 4,
24 and 52 weeks after surgery. Data were collected from medical records and entered into a
web based case report form (CRF) at each site by a research assistant. Baseline data was
obtained from values within 4 weeks prior to surgery; four-week outcomes within 2–8
weeks after surgery, 24-week outcomes within 16–32 weeks, and 52-week outcomes within
48–56 weeks. In cases of multiple data within these time frames, the data closest to the time
point were recorded. Laboratory values prior to preoperative transfusions were used as
baseline data.
We recorded 68 variables, including demographics, disease, indications for surgery, clinical,
laboratory and imaging data, and use of laparoscopy (See Supplemental Data 1 for variable
list). We used established clinical and data standards for outcome definitions (See
Supplemental Data 2).
Adverse events (AEs) included infection (including type), acute chest syndrome (ACS, for
SCD patients only), thrombotic events, reoperation, and death (see Appendix 2 for definition
of AEs). For children undergoing PS, we collected baseline and postoperative measurements
of the spleen size using ultrasound, and calculated splenic volume (expressed as percentage
of baseline volume) using the method of De Odorico [15].
Data quality
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We audited the first 50 subjects (including both retrospective and prospective subjects) to
determine the rate of erroneous data. Erroneous data were identified by a second review of
all primary source data, and comparing with final data in the registry. Erroneous data were
defined as either an error in data coding (i.e. the wrong value was recorded on the written
CRF or transcribed onto the electronic CRF), or failure to use the data from the paper CRF.
We audited all 100 subjects to measure the rate of missing data, including the rate of
submission of CRFs as well as individual variables. We defined a CRF as submitted if a
CRF had at least one completed variable submitted for that time point, and an individual
variable as submitted if there were any data recorded for that variable at that time point.
Data analysis
We summarized results into hematologic outcomes, short-term AEs (≤ 30 days after
surgery), and long-term AEs (31–365 days after surgery). This structure was chosen to
communicate important outcomes to all stakeholders, including families [3]. We analyzed
Am J Hematol. Author manuscript; available in PMC 2016 March 01.
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hematologic outcomes and AEs based on type of disease (HS versus SCD) as well as by
type of procedure (PS versus TS). Due to small number of children with other types of
CHA, detailed analysis of outcomes was limited to children with HS or SCD.
We determined differences between cohorts using Pearson’s Chi squared or Fisher’s exact
test for categorical data, and Mann–Whitney U test, Kuskal-Wallis rank sum test or
Wilcoxon signed ranks test for continuous data, using a two-tailed significance of 5%.
Comparisons of preoperative and postoperative symptoms were made using McNemar’s test
for matched data. Categorical variables were expressed as percentage, and continuous
variables by median and interquartile range (IQR) or mean ± standard deviation (SD). For
hematologic data, we graphically described trends of mean ± standard error (SE), and
confirmed differences between baseline and each time point by matched analysis of nonparametric continuous data using the Wilcoxon signed ranks test, with analysis limited to
children who had data at baseline and at that time point. All analyses were performed using
R version 3.0.2.

Results
NIH-PA Author Manuscript

Demographics
As of November 2014, 134 children were enrolled in the registry from 16 sites (mean 8.9
subjects/site, median 3 subjects/site), although this report is limited to the first 100 children
who reached at least one year after surgery (Table 1). There was an equal distribution of
boys and girls, with expected racial and ethnic disparity by disease type. Use of preoperative
vaccines and postoperative antibiotics was high. Most children had HS (n=40) or SCD
(n=50), with subtypes of SCD including hemoglobin SS (n=30) or SC (n=10). Ten children
had another type of CHA, including pyruvate kinase deficiency (n=1), alpha thalassemia/
hemoglobin E-Constant Spring (n=3), beta thalassemia intermedia (n=1), beta thalassemia
major (n=1), hemoglobin CC (n=1), hemoglobin Koln (n=1), or CHA, unspecified (n=2).
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The type of procedure differed by disease. For children with HS, 19/40 (48%) received a PS
and 21/40 (52%) received TS. For children with SCD, 34/50 (68%) received TS and 16/50
(32%) received a PS. The majority of children undergoing TS had an initial laparoscopic
approach (47/54, 87%). In contrast, only 12/46 (26%) of children with PS had a laparoscopic
approach, and 6/12 (50%) were converted to laparotomy.
Hematologic outcomes
Hereditary Spherocytosis—Most children with HS had resolution of their clinical
symptoms following TS or PS (Table 2). For children with HS, we found an increase in
hemoglobin (baseline 10.1 ± 1.8 gm/dl, 4 week 12.7 ± 1.5 gm/dl, 24 week 13.4 ± 2.1 gm/dl,
52 week 12.8 ± 1.6 gm/dl; mean ± SD), decrease in reticulocyte count (baseline 9.0 ± 4.4%,
4 week 2.2 ± 2.5%, 24 week 4.6 ± 2.8%, 52 week 4.5 ± 2.0%), and decrease in bilirubin
(baseline 3.0 ± 1.4 mg/dl, 4 week 0.7 ± 0.6 mg/dl, 24 week 1.0 ± 0.6 mg/dl, 52 week 1.1 ±
0.3 mg/dl) (Fig 1A–C). By matched analysis, the increase in hemoglobin was significant
(p<0.05) at each time point compared to baseline. Both TS and PS led to an increase in
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hemoglobin at all time points compared to baseline (Fig 1A–C), although there was not
adequate data to compare outcomes between TS and PS.
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Sickle Cell Disease—Children with SCD had resolution of their clinical symptoms
following TS or PS, including splenic sequestration or participation in a regular transfusion
program (Table 2). In contrast to children with HS, children with SCD had similar
hemoglobin, reticulocyte count, and serum bilirubin postoperatively compared to baseline
(Fig 2A–C). Both TS and PS resulted in similar hemoglobin after surgery compared to
baseline. The small number of children with SCD precluded comparison of outcomes
between TS and PS as well as comparison of outcomes between hemoglobin SS and SC
disease.
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Splenic Growth and Function following Partial Splenectomy—For all 35 children
undergoing PS, the measured splenic volume was stable over 1 year: (Fig 3; baseline volume
413 ± 328 ml (100%); 4 week 58 ± 66 ml (14%); 24 week 45 ± 35 ml (10%); 52 week 63 ±
42 ml (12%); expressed as mean ± standard deviation (SD) and percentage of baseline
volume). No child required a completion splenectomy during 1 year of follow-up. We were
not able to analyze preservation of splenic function following PS (i.e. nuclear medicine liver
spleen scans, Doppler splenic ultrasound, notations of Howell-Jolly bodies, etc.), as these
studies were not performed consistently across sites.
Adverse events
The overall rate of short-term AEs was 11%, with no death recorded. For children with HS,
there was a 2.5% rate of infection. In children with SCD, there was a 10.0% rate of infection
and 12.0% rate of acute chest syndrome (ACS).
The overall rate of long-term AEs was also 11%, with no deaths recorded. For children with
HS, there were no infections or thrombotic events, and one reoperation (3.1%) over one year
of follow-up. Children with SCD had a 14.3% rate of infection, including two with sepsis,
one with upper respiratory tract infection (URI), one with parainfluenza, one with influenza
B, and one unspecified. Children with SCD had a 9% rate of ACS and a 2% rate of blood
transfusion. There was one child (2%) with a thrombotic event, who had a transient ischemic
attack 24 weeks after TS.
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Data quality
Audit of the first 50 patients (24 retrospective, 26 prospective) demonstrated 5 erroneous
variables out of 4,873 entries (0.1%). All of these were with data coding, i.e. the wrong
value was recorded on the CRF or transcribed onto the electronic CRF, with no failures to
use the data from the paper CRF. Of note, there were 8 children with HS who were reported
to have splenic sequestration, which likely reflects an error in data coding.
Analysis of missing data showed that 92% (369 out of 400) of all CRFs were completed.
The rate of CRF completion was highest at early time points: 100% at baseline, 96% at 4
weeks, 91% at 24 weeks, and 82% at 52 weeks. Analysis of individual variables showed that
1 2,189 out of 16,400 (74.3%) were completed.
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Discussion
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For children with CHA, the outcomes following TS or PS are poorly defined, leaving
families and clinicians in a quandary when deciding between surgical therapies or surgical
vs medical therapies. Most existing studies in this area are either single center or small
multicenter reports, and are limited by use of non-standardized data (see review [3]).
Furthermore, many of the studies in this area were performed before the widespread use of
Prevnar-13 [17], and the current rate of infectious events following splenectomy is
unknown. In our current report from a patient registry of 100 children with CHA undergoing
TS or PS, we found that both procedures result in favorable clinical outcomes and have a
low rate of AEs over one year of follow-up. This observational study is the first multicenter
report using standardized data in this area, and should be of great value to families and
clinicians considering splenectomy.
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The clinical outcomes of TS and PS differ between diseases. For HS, all types of
splenectomy resulted in control of clinical symptoms as well as improvement in hematologic
laboratory parameters. Although our registry did not compare outcomes between PS and TS,
both procedures had improved hematologic outcomes after surgery, a finding consistent with
most previous literature [3, 4, 14, 18, 19]. A prospective randomized clinical trial will be
required to definitively compare surgical procedures or surgical vs medical therapies.
Finally, although control of clinical symptoms of primary importance to families, we
suggest that future studies of splenectomy examine the specific goals of families and
clinicians as they chose between surgical or medical therapies, as well as assessment of
satisfaction with the outcomes.
For children with SCD, all types of splenectomy control clinical symptoms, particularly the
need for transfusions, although there is no effect on hemoglobin or other hematologic
parameters. This finding is consistent with most previous literature [20–22], although some
single center case series have shown improvement in hemoglobin levels [23, 24]. Given the
heterogeneity of different types of SCD, a clinical trial will require a large number of
enrolled children to compare partial or total splenectomy, as well as to define the optimal
candidates for each procedure in terms of use of hydroxyurea, age, and functional splenic
status.
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There is a low overall rate of AEs after PS or TS, although children with SCD have
continued risks of infection and ACS, which is likely related to their underlying disease. In
contrast to reports describing a high rate of vascular thrombosis after splenectomy [25, 26],
we recorded only one child with a thrombotic event, and this event likely is attributable to
SCD as it occurred 24 weeks following surgery. However, as we collected only symptomatic
thrombotic events over one year, the long-term risk of vascular complications may be
greater than those clinically evident. We also found that no children required a completion
splenectomy during the one year observation period, in contrast to the 10–40% rate reported
in small case series over several years of follow-up [4, 14, 27, 28].
We learned several lessons about a registry that are helpful for the study of CHA. First, we
recognized that early definition of important issues for all stakeholders, including families,
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is essential. During pilot testing we collected 110 variables and later realized that many did
not address important concerns and/or were not routinely tested. Using a smaller data
dictionary allowed for less site burden and improved data quality. Second, optimal registry
design using standardized data is critical to maximize data quality. Our missing data rate is
similar to other large observational registries [29, 30]. Although the use of a protocol with
required tests would minimize missing data, we caution against mandating these practices
for an observational pediatric registry, as this may decrease the rate of enrollment [31].
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We observed several findings in regards to variability of care. Although this observational
study was not designed to compare outcomes between procedures or sites, we found a low
rate of laparoscopy in children undergoing PS, which may be due to the complex nature of
laparoscopy for PS or reflect clinical care patterns which are currently evolving towards
increased use of laparoscopy. In contrast to PS, TS is generally performed laparoscopically,
which is attractive to families as laparoscopic splenectomy results in a shorter length of stay
and less morbidity than an open procedure [3]. However, if given a choice between a
laparoscopic TS and an open PS, it is unclear which families would prefer, as both options
offer a different set of benefits. Furthermore, even if family preference would drive the
choice towards a given procedure, is this optimal for a child? Although these issues are
beyond the scope of this current report, we suggest that future study of splenectomy in CHA
should address how these issues affect the family decision-making process.
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There are several limitations to our study. First, this report has only one year of follow-up.
However these findings should be of great value to families and clinicians, as the rate of
sepsis following splenectomy is highest during the first year after surgery [32]. We do
recognize that understanding the long-term outcomes (i.e. decades) following TS or PS is
critical to understand the role of surgery, and plan to continue follow-up for several years
after surgery. Secondly, as an observational study, a registry does not allow for comparison
of surgical procedures or surgical versus medical therapies. Third, some important outcomes
such as splenic function following partial splenectomy are difficult to assess though an
observational study, as these tests are not performed consistently across sites. Finally, our
registry used an informed consent process that may have skewed the results, as the consent
process may change enrollment from a population based cohort to a selective cohort [33].
Although informed consent traditionally has been fundamental to clinical research, some
experts suggest that the consent process for registries should be reassessed, as the public
health value of this information may outweigh the risks to personal identity [33].
In conclusion, we found favorable clinical outcomes and a low rate of AEs in children with
CHA following PS or TS using a multicenter patient registry. These findings demonstrate
the great value as well as the inherent limitations of a patient registry, and define expected
outcomes of these procedures. As we accumulate a greater number of children in this
registry, extend long-term follow-up, we should enhance our understanding of these
procedures, facilitate the design of clinical trials, and engage all stakeholders in the decisionmaking process when considering surgery.
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Figure 1.

(A–C)-Hematologic outcomes following partial splenectomy or total splenectomy in 40
children with hereditary spherocytosis. Data represent hemoglobin (Panel A), reticulocyte
count (Panel B) or serum bilirubin (Panel C) at baseline, and at 4, 24, or 52 weeks after
partial splenectomy (n=19) or total splenectomy (n=21). All data expressed as mean, with
error bars representing standard error. Data on hemoglobin and bilirubin in TS group at 52
weeks had too few data entries to include in the analysis,
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Figure 2.

(A–C)-Hematologic outcomes following partial splenectomy or total splenectomy in 50
children with sickle cell disease. Data represent hemoglobin (Panel A), reticulocyte count
(Panel B) or serum bilirubin (Panel C) at baseline, and at 4, 24, or 52 weeks surgery after
partial splenectomy (n=16) or total splenectomy (n=34). All data expressed as mean, with
error bars representing standard error.
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Figure 3.

Splenic volume in 35 children following partial splenectomy, including 19 children with
hereditary spherocytosis and 16 children with sickle cell disease. Data represent mean
splenic volume at each time point measured by ultrasound as calculated using the method of
De Odorico [15].
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